- Home
- STN vs MDGL Comparison
STN vs MDGL Comparison
Compare STN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STN
- MDGL
- Stock Information
- Founded
- STN 1954
- MDGL 2011
- Country
- STN Canada
- MDGL United States
- Employees
- STN N/A
- MDGL N/A
- Industry
- STN Military/Government/Technical
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- STN Consumer Discretionary
- MDGL Health Care
- Exchange
- STN Nasdaq
- MDGL Nasdaq
- Market Cap
- STN 8.8B
- MDGL 7.1B
- IPO Year
- STN N/A
- MDGL N/A
- Fundamental
- Price
- STN $76.17
- MDGL $336.23
- Analyst Decision
- STN
- MDGL Buy
- Analyst Count
- STN 0
- MDGL 14
- Target Price
- STN N/A
- MDGL $351.67
- AVG Volume (30 Days)
- STN 130.0K
- MDGL 357.1K
- Earning Date
- STN 02-25-2025
- MDGL 02-26-2025
- Dividend Yield
- STN 0.80%
- MDGL N/A
- EPS Growth
- STN 6.58
- MDGL N/A
- EPS
- STN 2.27
- MDGL N/A
- Revenue
- STN $4,167,733,814.00
- MDGL $76,813,000.00
- Revenue This Year
- STN $15.93
- MDGL N/A
- Revenue Next Year
- STN $9.06
- MDGL $195.95
- P/E Ratio
- STN $33.72
- MDGL N/A
- Revenue Growth
- STN 13.64
- MDGL N/A
- 52 Week Low
- STN $73.18
- MDGL $189.00
- 52 Week High
- STN $88.42
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- STN 42.85
- MDGL 52.41
- Support Level
- STN $76.72
- MDGL $334.13
- Resistance Level
- STN $78.24
- MDGL $354.49
- Average True Range (ATR)
- STN 1.26
- MDGL 13.20
- MACD
- STN 0.06
- MDGL 0.16
- Stochastic Oscillator
- STN 55.68
- MDGL 43.12
About STN Stantec Inc
Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. The company is geographically diversified in three regional operating units namely Canada, United States and Global, offering similar services across all regions. The company offers services in various sectors across the project life cycle through five business operating units infrastructure, water, buildings, environmental services, and energy and resources. The company provides professional services in all phases of the project life cycle: planning, design, construction administration, commissioning, maintenance, decommissioning, and remediation.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.